IGF-1 et therapeutique du diabete non-insulino-dependant et de l'insulinoresistance

E. R. Froesch; T. Bianda; M. A. Hussain

IGF-1 et therapeutique du diabete non-insulino-dependant et de l'insulinoresistance

E. R. Froesch, T. Bianda, M. A. Hussain

Research output: Contribution to journal › Review article › peer-review

Abstract

Recombinant DNA technology has made large amounts of insulin-like growth factor-I (IGF-I) available for studies in animal models and humans. It has been shown that treatment with IGF-I is associated with increased insulin sensitivity in normal subjects as well as in patients with growth hormone deficiency, Type 1 and Type 2 diabetes mellitus and type A insulin- resistance. The metabolic effects of IGF-I appear to be beneficial in these conditions. The reported side effects of IGF-I, which may be largely due to overdosage, have limited its use to small and mostly short-term clinical studies.

Original language	English (US)
Pages (from-to)	261-267
Number of pages	7
Journal	Diabetes and Metabolism
Volume	22
Issue number	4
State	Published - Jul 1 1996
Externally published	Yes

Keywords

Type 2 diabetes mellitus
growth hormone
insulin resistance
insulin sensitivity
insulin-like growth factor-I

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism
Endocrinology

Cite this

@article{f7e35933dffa4014bf57239db62cb430,

title = "IGF-1 et therapeutique du diabete non-insulino-dependant et de l'insulinoresistance",

abstract = "Recombinant DNA technology has made large amounts of insulin-like growth factor-I (IGF-I) available for studies in animal models and humans. It has been shown that treatment with IGF-I is associated with increased insulin sensitivity in normal subjects as well as in patients with growth hormone deficiency, Type 1 and Type 2 diabetes mellitus and type A insulin- resistance. The metabolic effects of IGF-I appear to be beneficial in these conditions. The reported side effects of IGF-I, which may be largely due to overdosage, have limited its use to small and mostly short-term clinical studies.",

keywords = "Type 2 diabetes mellitus, growth hormone, insulin resistance, insulin sensitivity, insulin-like growth factor-I",

author = "Froesch, {E. R.} and T. Bianda and Hussain, {M. A.}",

year = "1996",

month = jul,

day = "1",

language = "English (US)",

volume = "22",

pages = "261--267",

journal = "Diabetes and Metabolism",

issn = "1262-3636",

publisher = "Elsevier Masson",

number = "4",

}

TY - JOUR

T1 - IGF-1 et therapeutique du diabete non-insulino-dependant et de l'insulinoresistance

AU - Froesch, E. R.

AU - Bianda, T.

AU - Hussain, M. A.

PY - 1996/7/1

Y1 - 1996/7/1

N2 - Recombinant DNA technology has made large amounts of insulin-like growth factor-I (IGF-I) available for studies in animal models and humans. It has been shown that treatment with IGF-I is associated with increased insulin sensitivity in normal subjects as well as in patients with growth hormone deficiency, Type 1 and Type 2 diabetes mellitus and type A insulin- resistance. The metabolic effects of IGF-I appear to be beneficial in these conditions. The reported side effects of IGF-I, which may be largely due to overdosage, have limited its use to small and mostly short-term clinical studies.

AB - Recombinant DNA technology has made large amounts of insulin-like growth factor-I (IGF-I) available for studies in animal models and humans. It has been shown that treatment with IGF-I is associated with increased insulin sensitivity in normal subjects as well as in patients with growth hormone deficiency, Type 1 and Type 2 diabetes mellitus and type A insulin- resistance. The metabolic effects of IGF-I appear to be beneficial in these conditions. The reported side effects of IGF-I, which may be largely due to overdosage, have limited its use to small and mostly short-term clinical studies.

KW - Type 2 diabetes mellitus

KW - growth hormone

KW - insulin resistance

KW - insulin sensitivity

KW - insulin-like growth factor-I

UR - http://www.scopus.com/inward/record.url?scp=0030015606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030015606&partnerID=8YFLogxK

M3 - Review article

C2 - 8767173

AN - SCOPUS:0030015606

VL - 22

SP - 261

EP - 267

JO - Diabetes and Metabolism

JF - Diabetes and Metabolism

SN - 1262-3636

IS - 4

ER -

IGF-1 et therapeutique du diabete non-insulino-dependant et de l'insulinoresistance

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this